A Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post Chemotherapy Consolidation for Epithelial Carcinoma of Ovarian, Tubal or Peritoneal Origin

Trial Profile

A Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post Chemotherapy Consolidation for Epithelial Carcinoma of Ovarian, Tubal or Peritoneal Origin

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2007

At a glance

  • Drugs Oregovomab (Primary)
  • Indications Ovarian cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms IMPACT-II
  • Sponsors Unither Pharmaceuticals
  • Most Recent Events

    • 06 Dec 2007 Primary endpoint not met - interim results reported by Unither Pharmaceuticals.
    • 06 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top